PREDY-NT 37.5/10 Tablets
Pregabalin (Sustained Release) 37.5mg with Nortriptyline Hydrochloride 10mg Tablets
Reference MRP
₹150.00
Standard Packaging
10 Strips x 10 Sustained-Release Tablets per carton (100 Tablets Box / Master Shipper: 60 Boxes)
PREDY-NT 37.5/10 Tablets provide balanced, round-the-clock neuropathic pain relief. Manufactured under strict Schedule M GMP standards by Redition Pharma, this formulation features sustained-release Pregabalin to modulate hyper-excited voltage-gated calcium channels in the spinal cord alongside Nortriptyline Hydrochloride to enhance descending noradrenergic inhibitory pain pathways. The sustained-release matrix ensures stable plasma levels, preventing peak-related dizziness while offering superior nocturnal analgesic coverage and restorative sleep.
Lic. 12116801000249Request batch Certificate of Analysis (COA), technical dossier, and institutional rate contracts.
Pharmacological Advantages & Clinical Evidence
- 01
Sustained-Release Pregabalin (37.5mg): Steady-state 24-hour plasma concentrations eliminating peak-related dizziness and daytime sedation.
- 02
Nortriptyline Hydrochloride (10mg): Amplifies descending noradrenergic inhibitory pain modulation and improves restorative sleep.
- 03
Synergistic 37.5/10 Low-Dose Ratio: Delivers potent clinical analgesia at lower individual doses with high patient tolerability.
- 04
Authentic Batch Verification: Batch No. BCT26743 with complete regulatory Certificate of Analysis (COA) compliance.
- 05
10 x 10 Tablets Packaging: Protected in moisture-barrier blister foils inside UV-resistant clinical mono-carton.
Clinical Indications
- —Diabetic Peripheral Neuropathic Pain (DPNP)
- —Post-Herpetic Neuralgia (PHN)
- —Cervical & Lumbar Radiculopathy / Sciatica
- —Spinal Cord Injury Neuropathic Pain
- —Fibromyalgia & Chronic Central Pain Syndromes
Technical Specifications
- Active Ingredient
- Pregabalin (Sustained Release), Nortriptyline Hydrochloride
- Dosage Form
- Sustained-Release Film-Coated Tablet
- Pharmacopoeial Standard
- IP / In-House Validated Monograph
- Formulation Category
- Dual Alpha-2-Delta Ligand & Tricyclic Neuropathic Analgesic
- Administration
- As directed by the physician (Schedule H Prescription). Typically 1 tablet once daily at bedtime, swallowed whole with water without crushing or chewing.
- Packaging Format
- 10 Strips x 10 Sustained-Release Tablets per carton (100 Tablets Box / Master Shipper: 60 Boxes)
- Storage & Stability
- Store between 10°C to 20°C in a dry place. Protect from direct sunlight and moisture. Tablet should be swallowed whole. | Shelf life: 24 Months from manufacturing date
Mechanism of Action
Pregabalin binds selectively to the alpha-2-delta auxiliary subunit of voltage-gated calcium channels in presynaptic neurons, decreasing calcium influx and suppressing the release of pro-nociceptive neurotransmitters (glutamate, substance P, and calcitonin gene-related peptide). Nortriptyline simultaneously blocks the reuptake of norepinephrine and serotonin at central synapses, reinforcing descending inhibitory control over dorsal horn nociceptive transmission.
Institutional FAQs
What is PREDY-NT 37.5/10 Tablets indicated for?
PREDY-NT 37.5/10 is indicated for the management of chronic neuropathic pain conditions, including diabetic peripheral neuropathy, nerve injury pain, sciatica, and post-herpetic neuralgia.
Why is the tablet formulated with Sustained Release (SR)?
The sustained-release formulation provides consistent therapeutic plasma concentrations over 24 hours, preventing the steep plasma spikes and troughs associated with immediate-release pregabalin that often cause dizziness and sedation.
Can PREDY-NT tablets be crushed or broken in half?
No. PREDY-NT must be swallowed whole with water to preserve the integrity of the sustained-release matrix. Crushing or chewing the tablet may cause rapid dumping of the active medication.
Procurement & Dossier Request for PREDY-NT 37.5/10 Tablets
Submit your hospital tender requirements, rate-contract bids, or Certificate of Analysis (COA) requests. Our regulatory trade desk dispatches validated batch documentation within 24 hours.
Founder & Managing Director
Nilesh Kumar
Direct Sales & Dispatch Line
+91 79877 79819Regulatory Dossiers & RFQ
reditionpharma@gmail.comRegistered Corporate Office
101, 1st Floor, Bhumi Park Society, Punagam Chorasi Bombay Market, Surat, Gujarat 395010, India